> **Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Clinical Studies on Coronary Artery Disease & Cardiac Interventions: A Review
Introduction
Coronary Artery Disease (CAD) is the leading cause of death globally, responsible for millions of deaths annually and placing a significant strain on healthcare resources [1]. This chronic inflammatory disease is characterized by the development of atherosclerotic plaques within the coronary arteries, which can restrict blood flow to the heart muscle, leading to a spectrum of clinical presentations, from stable angina to acute coronary syndromes (ACS), including myocardial infarction (heart attack) and sudden cardiac death. The management of CAD has undergone a remarkable evolution over the past several decades, driven by a deeper understanding of its pathophysiology and a continuous stream of innovations in diagnostic and therapeutic strategies. This review synthesizes the evidence from landmark clinical trials and recent research to provide a comprehensive overview of the current state of cardiac interventions for CAD, highlighting the shift towards a more personalized and evidence-based approach to patient care.
The Evolving Paradigm of Revascularization
The cornerstone of interventional cardiology is revascularization, the restoration of blood flow to the ischemic myocardium. The journey began with the advent of balloon angioplasty, a technique that mechanically widens stenotic arteries. This was followed by the introduction of bare-metal stents (BMS), which provided a scaffold to prevent acute vessel recoil and reduce restenosis rates compared to balloon angioplasty alone. However, the long-term efficacy of BMS was limited by in-stent restenosis, the gradual re-narrowing of the stented segment due to neointimal hyperplasia. This challenge was largely overcome by the development of drug-eluting stents (DES), which are coated with antiproliferative drugs that inhibit this process. Second and third-generation DES, with their thinner struts, more biocompatible polymers, and improved drug-delivery kinetics, have further enhanced safety and efficacy, establishing them as the standard of care for most patients undergoing percutaneous coronary intervention (PCI) [8] [27].
Landmark Clinical Trials: Shaping Contemporary Practice
A multitude of clinical trials have been instrumental in shaping our current approach to CAD management. The **COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)** trial was a pivotal study that randomized patients with stable CAD to either PCI with optimal medical therapy (OMT) or OMT alone. The trial found no difference in the primary endpoint of death or myocardial infarction between the two groups, although PCI was more effective in relieving angina. This landmark study underscored the critical importance of OMT as the foundation of care for stable CAD [3].
Subsequent trials have further refined our understanding of the role of revascularization. The **FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation)** and **FAME 2** trials demonstrated the superiority of FFR-guided PCI over angiography-guided PCI in patients with multivessel disease. FFR is a physiological index that measures the pressure gradient across a coronary stenosis, providing a more accurate assessment of its hemodynamic significance. By selectively stenting only the lesions that are causing ischemia, FFR-guided PCI improves outcomes and is more cost-effective [5].
More recently, the **ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches)** trial provided further insights into the management of stable CAD. This large-scale trial randomized patients with stable CAD and moderate-to-severe ischemia to either an initial invasive strategy (PCI or coronary artery bypass grafting [CABG]) or a conservative strategy (OMT). The results showed no significant difference in the primary composite endpoint of cardiovascular death, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. However, the invasive strategy was associated with a greater improvement in angina-related quality of life, particularly in patients with more frequent angina [4].
Innovations in Interventional Cardiology
The field of interventional cardiology is in a constant state of innovation, with new technologies and techniques continually emerging to address unmet clinical needs. **Intravascular imaging**, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), provides high-resolution images of the coronary arteries from within, allowing for precise lesion assessment, stent sizing, and optimization of stent deployment. These imaging modalities have been shown to improve clinical outcomes, particularly in complex PCI procedures [14] [15] [16].
**Intravascular lithotripsy (IVL)** is a novel therapy for the treatment of heavily calcified coronary lesions. Calcified plaques are often resistant to conventional balloon angioplasty and can impede stent expansion, leading to suboptimal results. IVL utilizes sonic pressure waves to fracture the calcium within the plaque, modifying its compliance and facilitating stent delivery and expansion [33].
**Bioresorbable vascular scaffolds (BVS)** were developed with the intention of providing temporary vessel support and then being completely absorbed, leaving behind a healed and vasoreactive artery. While the initial enthusiasm for BVS has been tempered by concerns about scaffold thrombosis, the concept of a "leave-nothing-behind" approach remains an attractive goal, and research in this area is ongoing [27].
**Robotic-assisted PCI** is an emerging technology that allows interventional cardiologists to perform procedures with greater precision and control, while also reducing their exposure to radiation [29] [30] [31]. While still in its early stages of adoption, robotic PCI has the potential to enhance the safety and efficacy of complex interventions.
The Central Role of Optimal Medical Therapy
It is crucial to emphasize that interventional procedures are just one component of a comprehensive management strategy for CAD. **Optimal medical therapy (OMT)** is the cornerstone of treatment for all patients with CAD, regardless of whether they undergo revascularization. OMT includes:
- **Antiplatelet therapy:** Aspirin and P2Y12 inhibitors (e.g., clopidogrel, prasugrel, ticagrelor) are essential to prevent blood clots.
- **Lipid-lowering therapy:** Statins are the first-line agents for lowering LDL cholesterol, a major driver of atherosclerosis. Other agents, such as ezetimibe and PCSK9 inhibitors, may be added in high-risk patients who do not achieve their LDL goals with statins alone.
- **Antihypertensive therapy:** Beta-blockers, ACE inhibitors, and angiotensin receptor blockers (ARBs) are used to control blood pressure and reduce the workload on the heart.
- **Lifestyle modification:** A heart-healthy diet, regular physical activity, smoking cessation, and weight management are fundamental to improving long-term outcomes.
Conclusion
The management of coronary artery disease has been transformed by a relentless pursuit of scientific knowledge and technological innovation. Landmark clinical trials have provided the evidence base for a more nuanced and patient-centered approach, shifting the focus from simply treating angiographic stenoses to a more holistic strategy that incorporates physiological assessment, advanced imaging, and aggressive medical therapy. While PCI remains a vital tool for the relief of angina and the treatment of acute coronary syndromes, the importance of optimal medical therapy as the foundation of care cannot be overstated. The future of interventional cardiology lies in the continued development of novel technologies that can further improve the safety and efficacy of revascularization, as well as a deeper understanding of the complex interplay between plaque biology, hemodynamics, and clinical outcomes. By embracing a multidisciplinary and evidence-based approach, we can continue to improve the lives of patients with coronary artery disease.
References
1. Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023. J. Am. Coll. Cardiol. 2025;86:2167–2243. doi: 10.1016/j.jacc.2025.08.015. 2. Ahmadi A., Argulian E., Leipsic J., Newby D.E., Narula J. From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019;74:1608–1617. doi: 10.1016/j.jacc.2019.08.012. 3. Nowbar A.N., Rajkumar C., Al-Lamee R.K., Francis D.P. Controversies in revascularisation for stable coronary artery disease. Clin. Med. 2021;21:114–118. doi: 10.7861/clinmed.2020-0922. 4. Maron D.J., Hochman J.S., Reynolds H.R., Bangalore S., O’Brien S.M., Boden W.E., Chaitman B.R., Senior R., López-Sendón J., Alexander K.P., et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N. Engl. J. Med. 2020;382:1395–1407. doi: 10.1056/NEJMoa1915922. 5. De Bruyne B., Pijls N.H., Kalesan B., Barbato E., Tonino P.A., Piroth Z., Jagic N., Mobius-Winckler S., Rioufol G., Witt N., et al. Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease. N. Engl. J. Med. 2012;367:991–1001. doi: 10.1056/NEJMoa1205361. 6. Cortese B., Micheli A., Picchi A., Coppolaro A., Bandinelli L., Severi S., Limbruno U. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010;96:1291–1296. doi: 10.1136/hrt.2010.195057. 7. Jeger R.V., Farah A., Ohlow M.-A., Mangner N., Möbius-Winkler S., Leibundgut G., Weilenmann D., Wöhrle J., Richter S., Schreiber M., et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): An open-label randomised non-inferiority trial. Lancet. 2018;392:849–856. doi: 10.1016/S0140-6736(18)31719-7. 8. Stefanini G.G., Holmes D.R., Jr. Drug-Eluting Coronary-Artery Stents. N. Engl. J. Med. 2013;368:254–265. doi: 10.1056/NEJMra1210816. 9. Weisz G., Metzger D.C., Caputo R.P., Delgado J.A., Marshall J.J., Vetrovec G.W., Reisman M., Waksman R., Granada J.F., Novack V., et al. Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study. J. Am. Coll. Cardiol. 2013;61:1596–1600. doi: 10.1016/j.jacc.2012.12.045. 10. Fazmin I.T., Ali J.M. Hybrid Coronary Revascularisation: Indications, Techniques, and Outcomes. J. Clin. Med. 2025;14:880. doi: 10.3390/jcm14030880. 11. Al-Lamee R., Thompson D., Dehbi H.-M., Sen S., Tang K., Davies J., Keeble T., Mielewczik M., Kaprielian R., Malik I.S., et al. Percutaneous coronary intervention in stable angina (ORBITA): A double-blind, randomised controlled trial. Lancet. 2018;391:31–40. doi: 10.1016/S0140-6736(17)32714-9. 12. Rajkumar C.A., Foley M.J., Ahmed-Jushuf F., Nowbar A.N., Simader F.A., Davies J.R., O’kAne P.D., Haworth P., Routledge H., Kotecha T., et al. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. N. Engl. J. Med. 2023;389:2319–2330. doi: 10.1056/NEJMoa2310610. 13. Mézquita A.J.V., Biavati F., Falk V., Alkadhi H., Hajhosseiny R., Maurovich-Horvat P., Manka R., Kozerke S., Stuber M., Derlin T., et al. Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: A Consensus Statement from the Quantitative Cardiovascular Imaging Study Group. Nat. Rev. Cardiol. 2023;20:696–714. doi: 10.1038/s41569-023-00880-4. 14. Föllmer B., Williams M.C., Dey D., Arbab-Zadeh A., Maurovich-Horvat P., Volleberg R.H.J.A., Rueckert D., Schnabel J.A., Newby D.E., Dweck M.R., et al. Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries. Nat. Rev. Cardiol. 2024;21:51–64. doi: 10.1038/s41569-023-00900-3. 15. van Herten R.L.M., Lagogiannis I., Leiner T., Išgum I. The role of artificial intelligence in coronary CT angiography. Neth. Heart J. 2024;32:417–425. doi: 10.1007/s12471-024-01901-8. 16. Wu J., Yang D., Zhang Y., Xian H., Weng Z., Ji L., Yang F. Non-invasive imaging innovation: FFR-CT combined with plaque characterization, safeguarding your cardiac health. J. Cardiovasc. Comput. Tomogr. 2024;19:152–158. doi: 10.1016/j.jcct.2024.08.008. 17. Bottardi A., Prado G.F.A., Lunardi M., Fezzi S., Pesarini G., Tavella D., Scarsini R., Ribichini F. Clinical Updates in Coronary Artery Disease: A Comprehensive Review. J. Clin. Med. 2024;13:4600. doi: 10.3390/jcm13164600. 18. Vrints C., Andreotti F., Koskinas K.C., Rossello X., Adamo M., Ainslie J., Banning A.P., Budaj A., Buechel R.R., Chiariello G.A. 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) Eur. Heart J. 2024;45:3515–3537. 19. Xie Y., Han W., Wang S., Jia W., Wang Y., Li J., Chen B. Advantages of hybrid intravascular ultrasound-optical coherence tomography system in clinical practice. Front. Cardiovasc. Med. 2025;12:1595889. doi: 10.3389/fcvm.2025.1595889. 20. Liu B., Zhou Q. High-Resolution Intravascular Ultrasound: Advances in Coronary Plaque Characterization. Curr. Treat. Options Cardiovasc. Med. 2025;27:49. doi: 10.1007/s11936-025-01098-y. 21. van Veelen A., van der Sangen N.M.R., Delewi R., Beijk M.A.M., Henriques J.P.S., Claessen B.E.P.M. Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. J. Clin. Med. 2022;11:1361. doi: 10.3390/jcm11051361. 22. Westwood M.E., Armstrong N., Worthy G., Fayter D., Ramaekers B.L.T., Grimm S., Buksnys T., Ross J., Mills N.L., Body R., et al. Optimizing the Use of High-Sensitivity Troponin Assays for the Early Rule-out of Myocardial Infarction in Patients Presenting with Chest Pain: A Systematic Review. Clin. Chem. 2021;67:237–244. doi: 10.1093/clinchem/hvaa280. 23. Farmakis D., Mueller C., Apple F.S. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. Eur. Heart J. 2020;41:4050–4056. doi: 10.1093/eurheartj/ehaa083. 24. Mehta N.N., deGoma E., Shapiro M.D. IL-6 and Cardiovascular Risk: A Narrative Review. Curr. Atheroscler. Rep. 2024;27:12. doi: 10.1007/s11883-024-01259-7. 25. Bouzidi N., Gamra H. Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention. BMC Cardiovasc. Disord. 2023;23:586. doi: 10.1186/s12872-023-03570-8. 26. Qiu Y., Hao W., Guo Y., Guo Q., Zhang Y., Liu X., Wang X., Nie S. The association of lipoprotein (a) with coronary artery calcification: A systematic review and meta-analysis. Atherosclerosis. 2024;388:117405. doi: 10.1016/j.atherosclerosis.2023.117405. 27. Nissen S.E., Ni W., Shen X., Wang Q., Navar A.M., Michael L.F., Haupt A., Krege J.H. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2025;333:222–231. doi: 10.1001/jama.2024.24017. 28. Liu Y., Jia S.-D., Yao Y., Tang X.-F., Xu N., Jiang L., Gao Z., Chen J., Yang Y.-J., Gao R.-L., et al. Impact of high-sensitivity C-reactive protein on coronary artery disease severity and outcomes in patients undergoing percutaneous coronary intervention. J. Cardiol. 2020;75:60–65. doi: 10.1016/j.jjcc.2019.06.012. 29. Katamine M., Minami Y., Nagata T., Asakura K., Muramatsu Y., Kinoshita D., Fujiyoshi K., Ako J. High-sensitivity C-reactive protein, plaque vulnerability and adverse events in patients with stable coronary disease: An optical coherence tomography study. Int. J. Cardiol. 2025;421:132924. doi: 10.1016/j.ijcard.2024.132924. 30. Shahrori Z.M.F., Frazzetto M., Mahmud S.H., Alghwyeen W., Cortese B. Drug-Coated Balloons: Recent Evidence and Upcoming Novelties. J. Cardiovasc. Dev. Dis. 2025;12:194. doi: 10.3390/jcdd12050194. 31. Korjian S., McCarthy K.J., Larnard E.A., Cutlip D.E., McEntegart M.B., Kirtane A.J., Yeh R.W. Drug-coated balloons in the management of coronary artery disease. Circ. Cardiovasc. Interv. 2024;17:E013302. doi: 10.1161/CIRCINTERVENTIONS.123.013302. 32. Stefanini G.G., Byrne R.A., Windecker S., Kastrati A. State of the art: Coronary artery stents—Past, present and future. EuroIntervention. 2017;13:706–716. doi: 10.4244/EIJ-D-17-00557. 33. Liu J., Bursill C. When stents become plaques: In-stent neoatherosclerosis. Nat. Rev. Cardiol. 2025 doi: 10.1038/s41569-025-01241-z. 34. Stevenson A., Kirresh A., Ahmad M., Candilio L. Robotic-Assisted PCI: The Future of Coronary Intervention? Cardiovasc. Revascularization Med. 2022;35:161–168. doi: 10.1016/j.carrev.2021.03.025. 35. Mahmud E., Madder R.D., Wohns D.H., Schussler J.M., Salisbury A., Campbell P., Patel T.M., Lombardi W.L., Nicholson W.J., Parikh M.A., et al. Robotic-Assisted Percutaneous Coronary Intervention: Final Results of the PRECISION and PRECISION GRX Studies. J. Soc. Cardiovasc. Angiogr. Interv. 2025;4:103655. doi: 10.1016/j.jscai.2025.103655. 36. Roguin A., Wu P., Cohoon T., Gul F., Nasr G., Premyodhin N., Kern M.J. Update on Radiation Safety in the Cath Lab—Moving Toward a “Lead-Free” Environment. J. Soc. Cardiovasc. Angiogr. Interv. 2023;2:101040. doi: 10.1016/j.jscai.2023.101040. 37. Fazmin I.T., Ali J.M. Hybrid Coronary Revascularisation: Indications, Techniques, and Outcomes. J. Clin. Med. 2025;14:880. doi: 10.3390/jcm14030880. 38. Karimi Galougahi K., Patel S., Shlofmitz R.A., Maehara A., Kereiakes D.J., Hill J.M., Stone G.W., Ali Z.A. Calcific Plaque Modification by Acoustic Shock Waves: Intravascular Lithotripsy in Coronary Interventions. Circ. Cardiovasc. Interv. 2021;14:E009354. doi: 10.1161/CIRCINTERVENTIONS.120.009354. 39. Nicholls S.J., Ni W., Rhodes G.M., Nissen S.E., Navar A.M., Michael L.F., Haupt A., Krege J.H. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2025;333:222–231. doi: 10.1001/jama.2024.24017. 40. Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., Fonseca F., Nicolau J., Koenig W., Anker S.D., et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017;377:1119–1131. doi: 10.1056/NEJMoa1707914. 41. Nidorf S.M., Fiolet A.T.L., Mosterd A., Eikelboom J.W., Schut A., Opstal T.S.J., The S.H.K., Xu X.-F., Ireland M.A., Lenderink T., et al. Colchicine in Patients with Chronic Coronary Disease. N. Engl. J. Med. 2020;383:1838–1847. doi: 10.1056/NEJMoa2021372. 42. Aggarwal R., Bhatt D.L., Szarek M., Cannon C.P., Leiter L.A., Inzucchi S.E., Lopes R.D., McGuire D.K., Lewis J.B., Riddle M.C., et al. Effect of sotagliflozin on major adverse cardiovascular events: A prespecified secondary analysis of the SCORED randomised trial. Lancet Diabetes Endocrinol. 2025;13:321–332. doi: 10.1016/S2213-8587(24)00362-0. 43. McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L., Kosiborod M.N., Martinez F.A., Ponikowski P., Sabatine M.S., Anand I.S., Bělohlávek J., et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2019;381:1995–2008. doi: 10.1056/NEJMoa1911303. 44. Packer M.P., Anker S.D., Butler J., Filippatos G., Pocock S.J., Carson P., Januzzi J., Verma S., Tsutsui H., Brueckmann M., et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N. Engl. J. Med. 2020;383:1413–1424. doi: 10.1056/NEJMoa2022190. 45. Kim K., Ginsberg H.N., Choi S.H. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes Metab. J. 2022;46:517. doi: 10.4093/dmj.2022.0198. 46. Vignarajah A., Oro P., El Dahdah J., Vigneswaramoorthy N., Vest A.R., Shah G. All-cause mortality and cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and heart failure with reduced ejection fraction. Am. Heart J. Plus Cardiol. Res. Pract. 2025;60:100676. doi: 10.1016/j.ahjo.2025.100676. 47. Lincoff A.M., Brown-Frandsen K., Colhoun H.M., Deanfield J., Emerson S.S., Esbjerg S., Hardt-Lindberg S., Hovingh G.K., Kahn S.E., Kushner R.F., et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N. Engl. J. Med. 2023;389:2221–2232. doi: 10.1056/NEJMoa2310563. 48. Gao M., Tang M., Ho W., Teng Y., Chen Q., Bu L., Xu X., Zhang X.-Q. Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis. ACS Nano. 2023;17:17721–17739. doi: 10.1021/acsnano.3c00958. 49. Tao Y., Lan X., Zhang Y., Fu C., Liu L., Cao F., Guo W. Biomimetic nanomedicines for precise atherosclerosis theranostics. Acta Pharm. Sin. B. 2022;13:4442. doi: 10.1016/j.apsb.2022.11.014. 50. Nankivell V., Vidanapathirana A.K., Hoogendoorn A., Tan J.T.M., Verjans J., Psaltis P.J., Hutchinson M.R., Gibson B.C., Lu Y., Goldys E., et al. Targeting macrophages with multifunctional nanoparticles to detect and prevent atherosclerotic cardiovascular disease. Cardiovasc. Res. 2024;120:819. doi: 10.1093/cvr/cvae099. 51. The University of Edinburgh Artificial Blood Vessels Could Improve Heart Bypass Outcomes. [(accessed on 4 April 2025)]. Available online: https://www.ed.ac.uk/news/2024/artificial-blood-vessels-could-improve-heart-bypas. 52. Lang Z., Chen T., Zhu S., Wu X., Wu Y., Miao X., Wang Q., Zhao L., Zhu Z., Xu R.X. Construction of vascular grafts based on tissue-engineered scaffolds. Mater. Today Bio. 2024;29:101336. doi: 10.1016/j.mtbio.2024.101336. 53. Ratner B. Vascular Grafts: Technology Success/Technology Failure. BME Front. 2023;4:0003. doi: 10.34133/bmef.0003. 54. Pang A.S.-R., Dinesh T., Pang N.Y.-L., Dinesh V., Pang K.Y.-L., Yong C.L., Lee S.J.J., Yip G.W., Bay B.H., Srinivasan D.K. Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis. Molecules. 2024;29:2873. doi: 10.3390/molecules29122873. 55. ‘This is Revolutionary!’: Breakthrough Cholesterol Treatment Can Cut Levels by 69% After One Dose. BBC Science Focus Magazine. [(accessed on 23 December 2025)]. Available online: https://www.sciencefocus.com/news/new-cholesterol-treatment-could-be-revolutionary-verve. 56. Shakya S., Shrestha A., Robinson S., Randall S., Mnatzaganian G., Brown H., Boyd J., Xu D., Lee C.M.Y., Brumby S., et al. Global comparison of the economic costs of coronary heart disease: A systematic review and meta-analysis. BMJ Open. 2025;15:e084917. doi: 10.1136/bmjopen-2024-084917.